Sponsored Symposia

GSK Sponsored Dinner Symposium: Optimising outcomes at first relapse: The role of BCMA-based ADC in RRMM

Time: 
6:30 PM - 8:00 PM

Speakers: 
Prof Suzanne Trudel, Ontario Cancer Institute / University of Toronto

Chairperson:
Dr Joy Ho, Royal Prince Alfred Hospital

Location: 
516, NZICC

Synopsis:
BCMA is a promising therapeutic target in multiple myeloma, with an expanding range of BCMA-directed treatment options now available. Join Prof Suzanne Trudel and leading Australian haematologists as they review the clinical evidence for belantamab mafodotin (BLENREP) and share real-world experience and practical insights on optimising outcomes in patients with relapsed/refractory multiple myeloma (RRMM) at first relapse.

Novartis Sponsored Dinner Symposium: Today’s practice, tomorrow’s potential: Advancing patient-centred care and quality of life in ITP and PNH

Time: 
7:00 PM - 8:30 PM

Speakers: 
Dr Danny Hsu, MBBS, FRACP, FRCPA
Danielle Boyle, ITP ANZ
Chhean Khoun, PNH SAA

Chairperson:
Dr Danny Hsu, MBBS, FRACP, FRCPA

Location: 
503/504, NZICC

Synopsis:
Bringing together science and lived experience to shape the future of care in ITP and PNH.
Educational Objectives
o    Review the current state of play in ITP and PNH and discuss why the conversation needs to evolve. 
o    Recognise the multidimensional burden of ITP and PNH beyond traditional clinical outcomes.
o    Identify key unmet needs affecting patients' quality of life, emotional wellbeing, and treatment experience.
o    Understand how patient priorities can inform shared decision-making and treatment goal setting.
o    Review emerging therapeutic approaches that may address current unmet needs and treatment burden.
o    Apply practical strategies to integrate patient voice into everyday clinical practice.

BeOne Sponsored Breakfast Symposium: Optimising outcomes in CLL: From treatment selection to ongoing patient support

Time: 
7:00 AM - 8:15 AM, (Breakfast served from 6:30 AM)

Speakers: 
Prof Stephen Opat, Monash Health
Prof Rob Weinkove, Malaghan Institute of Medical Research

Location: 
516, NZICC

Synopsis:
Choosing the Right Therapy for Patients with CLL: A Practical Approach to Personalised Treatment Selection
In Australia, the treatment landscape for CLL has evolved rapidly, with clinicians now able to choose from multiple targeted therapies across both treatment-naïve and relapsed/refractory settings. This presentation will explore a practical, patient-centred approach to treatment selection, drawing on current CLL guidelines and the latest clinical evidence. Key considerations will include efficacy and safety of available treatment options, as well as patient-specific factors. Through the lens of real-world clinical decision-making, the session will provide a practical framework to support personalised treatment selection in contemporary CLL practice.

Supporting Patients Through CLL Therapy: Practical Strategies for Supportive Care and Infection Prevention
With advances in targeted therapies transforming outcomes in CLL, supportive care has become a critical component of patient management. This presentation will review contemporary approaches to infection prevention and supportive care throughout the treatment journey, including risk assessment, immunoglobulin replacement for hypogammaglobulinaemia, practical management considerations during targeted therapy, and strategies to enhance patient and clinician education.

SOBI Sponsored Breakfast Symposium: Navigating r/r DLBCL: A practical pathway for patients in metro or community practice

Time: 
7:00 AM - 8:15 AM, (Breakfast served from 6:30 AM)

Speakers: 
Dr Wendy Osbourne, (Virtual Presenter)
Dr Adrian Minson, Peter MacCallum Cancer Centre / Royal Melbourne Hospital

Location: 
503 & 504, NZICC

Synopsis:
This symposium will inform haematologists and multidisciplinary teams about the care pathways for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) across metropolitan and community settings. Chaired by Dr Adrian Minson, the session will provide an overview of the LOTIS-2 evidence base for loncastuximab tesirine, alongside a broader exploration of the Australian treatment landscape. Joining virtually from the UK, Dr Wendy Osborne will share broader international perspective and experience, touching on general aspects of treatment and patient management. An open discussion will follow, giving participants the opportunity to reflect on the evidence and insights shared, in support of informed, patient-centred decisions in practice.

Gilead Sponsored Dinner Symposium: CAR T-cell therapy in R/R LBCL: Practical insights for contemporary clinical practice

Time: 
6:30 PM - 9:30 PM 
Doors open at 18:30, session 19:00 - 21:30 | This Dinner Symposia is being held offsite.

Speakers: 
Prof Anna Sureda, Institut Catala d'Oncologia

Chairperson:
Prof Cameron Turtle, University of Sydney

Location: 
Elliot Room at Crown Plaza Auckland (5min walk), 128 Albert Street, Auckland

Synopsis:
CAR T-cell therapy offers the potential for durable remission in patients with R/R LBCL, yet many patients still miss the opportunity to benefit. Join international experts as they explore how clinicians can optimise access, treatment timing, and long-term outcomes through evidence-based, real-world clinical practice. This session is free to attend, but space is limited.

Johnson & Johnson Sponsored Dinner Symposium: Towards cure: The next chapter in multiple myeloma

Time: 
7:00 PM - 8:30 PM

Speakers: 
Prof. Nizar Jacques Bahlis, Arnie Charbonneau Cancer Research Institute

Location: 
503 & 504, NZICC

Synopsis:
This symposium will provide an overview of emerging evidence in the treatment of newly diagnosed and relapsed or refractory myeloma.
The program will highlight advances across the treatment continuum, including:
•    Monoclonal antibody–based therapies
•    Next-generation immunotherapies
•    New data that may shape future treatment strategies
Together, these discussions will explore a defining question in myeloma care: Is a cure within reach?

Incyte Sponsored Breakfast Symposium: Changing the goal posts in MPN – disease modification with targeted therapy

Time: 
7:00 AM - 8:15 AM, (Breakfast served from 6:30 AM)

Speakers: 
Peter Browett, University of Auckland, Auckland City Hospital
Zi Ng, Royal Perth Hospital
Andrew Perkins, Alfred Health
Marc Ellis, Concord Hospital

Chairperson:
Peter Browett, University of Auckland, Auckland City Hospital

Location: 
516, NZICC

Synopsis:
This MPN Symposium is designed to update haematologists on the latest in novel treatments and proposed endpoints in the rapidly changing field of myeloproliferative neoplasms. 
Leading experts from Australia and New Zealand will discuss whether recent therapeutic discoveries demonstrate that we can now change the natural history of disease, not just alleviate symptoms.